Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Discover why indices rise or fall, examining earnings, macro data, and policy factors that shape broad market direction.
21,369 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
AI ambitions collide with power limits. This article explains the gigawatt pivot, why it matters for investors, and w...
Micron stock has surged dramatically, but savvy investors are asking: is it still a bargain? This article breaks down...
Raymond James raises its price target on Phillips 66 to $205, citing a peak in refining margins and geopolitical tail...
Condo financing faces new insurance hurdles as lenders adjust rules; affordability hinges on policy shifts and region...
New research finds CFOs overseeing AI projects unlock significantly more value, with 76% reporting strong gains when ...
GameStop's latest SEC filing confirms it still holds 4,710 BTC, ending weeks of speculation over on-chain moves. The ...
If you’ve never invested passively, the idea of evaluating a syndicator can feel intimidating. This guide breaks down...
Qualcomm is trading at a discount to peers while building a strong AI silicon footprint. With a June Investor Day and...
As Xeris prepares to unpack its Q1 2026 results, investors want clarity on revenue, cash runway, and pipeline milesto...
This guide digs into plains (pagp) 2026 earnings, translating a complex earnings transcript into practical insights f...
Despite a tepid hiring climate, new college graduates can still land in high-demand fields. Healthcare support, cyber...